Arriaga JM, Ronaldson-Bouchard K, Picech F, Nunes de Almeida F, Afari S, Chhouri H, Vunjak-Novakovic G, Abate-Shen C. “In vivo genome-wide CRISPR screening identifies CITED2 as a driver of prostate cancer bone metastasis.” Oncogene (2024) Mar 7. PMID: 38454137
Vasciaveo A*, Arriaga JM*, de Almeida FN*, Zou M, Douglass EF, Picech F, Shibata M, Rodriguez-Calero A, de Brot S, Mitrofanova A, Chua CW, Karan C, Realubit R, Pampou S, Kim JY, Afari SN, Mukhammadov T, Zanella L, Corey E, Alvarez MJ, Rubin MA, Shen MM, Califano A, Abate-Shen C. “OncoLoop: A Network-Based Precision Cancer Medicine Framework.”Cancer Discov. (2023) Feb 6;13(2):386-409. PMID: 36374194
Arriaga, JM.,Panja, S., Alshalalfa, M., Zhao, J., Zou, M., Giacobbe, A., Madubata, C. J., Kim, J. Y., Rodriguez, A., Coleman, I., Virk, R., Hibshoosh, H., Ertunc, O., Oznek, B., Fountain, J., Karnes, R. J., Luo, J., Antonarakis, E. S., Nelson, P., Feng, F. Y., Rubin, M. A., De Marzo, A. M., Rabadan, R., Sims, P. A., Mitrofanova, A., and Abate-Shen, C. “A MYC and RAS co-activation signature in localized prostate cancer drives bone metastasis and castration resistance.” Nature Cancer (2020) 1, 1082–1096. PMID: 34085047.
Ager C, Obradovic A, Arriaga JM, Chaimowitz, Califano A, Abate-Shen C, and Drake C. “Longitudinal Immune Profiling Reveals Unique Myeloid and T Cell Phenotypes Associated with Spontaneous Immunoediting in a Novel Prostate Tumor Model.” Cancer Immunol Res. (2021) May;9(5):529-541. PMID: 33637604
Aytes A, Giacobbe A, Mitrofanova A, Ruggero K, Cyrta J, Arriaga JM, Palomero L, Farran-Matas S, Rubin MA, Shen MM, Califano A and Abate-Shen C. “NSD2 is a conserved driver of metastatic prostate cancer progression” Nat Commun. 9: 5201. PMCID: PMC6281610.
Arriaga JM and Abate-Shen C. “Genetically-engineered mouse models of prostate cancer in the post-genomic era.” Invited Review.Cold Spring Harb Perspect Med (2017) Apr 16. Pii: a030528 PMID: 29661807
Arriaga JM, Bravo AI, Mordoh J, Bianchini M. “Metallothionein 1G promotes differentiation of HT-29 human colorectal cancer cells.” Oncol Rep2017 May;37(5):2633-2651. PMID: 28393194
Arriaga JM, Greco A, Mordoh J, Bianchini M. “Metallothionein 1G and zinc sensitize human colorectal cancer cells to chemotherapy”. Mol Cancer Ther. 2014 May;13(5):1369-81. PMID: 24634414
Tapia IJ, Aris M, Arriaga JM,Blanco PA, Mazzobre MF,Vega J, Mordoh J,Barrio MM. “Development of a novel methodology for cryopreservation of melanoma cells applied to CSF470 therapeutic vaccine.” Cryobiology 2013 Oct;67(2):163-9 PMID: 23850827
Roberti MP, Rocca YS, Amat M, Pampena MB, Loza J, Coló F, Fabiano V, Loza CM, Arriaga JM, Bianchini M, Barrio MM, Bravo AI, Domenichini E, Chacón R, Mordoh J, Levy EM. “IL-2- or IL-15-activated NK cells enhance Cetuximab-mediated activity against triple-negative breast cancer in xenografts and in breast cancer patients.” Breast Cancer Res Treat. 2012 Dec;136(3):659-71. PMID: 23065032.
Arriaga JM,Bravo IA, Bruno L, Morales Bayo S, Hannois A, Sanchez Loria F, Pairola F, Huertas E, Roberti MP, Rocca YS, Aris M, Barrio MM, Baffa Trasci S, Levy EM, Mordoh J, Bianchini M. “Combined metallothioneins and p53 proteins expression as a prognostic marker in patients with Dukes stage B and C colorectal cancer.” Hum Pathol. 2012 Oct;43(10):1695-703. PMID: 22516242
Roberti MP, Arriaga JM, Quintá HR, Bravo IA, Levy EM, Mordoh J, Barrio MM. “Protein expression changes during human triple negative breast cancer cell line progression to lymph node metastasis in a xenografted model in nude mice.” Cancer Biol Ther. 2012 Sep;13(11):1123-40. PMID: 22825326.
Arriaga JM,Levy EM, Bravo AI, Bayo SM, Amat M, Aris M, Hannois A, Bruno L, Roberti MP, Loria FS, Pairola A, Huertas E, Mordoh J, Bianchini M. “Metallothionein expression in colorectal cancer: relevance of different isoforms for tumor progression and patient survival.” Hum Pathol. 2012 Feb;43(2):197-208. Epub 2011 Aug 4 PMID: 21820154
Rocca YS; Roberti MP; Arriaga JM; Amat M; Luisina Bruno; Pampena MB; Huertas E; Sánchez Loria F; Pairola A; Bianchini M; Mordoh J; Levy EM. “Altered Phenotype In Peripheral Blood And Tumor-associated Natural Killer Cells From Colorectal Cancer Patients”. Innate Immun.2013 Feb; 19(1):76-85. PMID: 22781631.
Aris M, Rodríguez Zubieta M, Colombo M, Arriaga JM, Bianchini M, Alperovich M, Bravo AI, Barrio MM, Mordoh JM. “MART-1 and gp100 -Expressing and -Non-Expressing Melanoma Cells are Equally Proliferative in Tumors and Clonogenic In vitro” J Invest Dermatol.2012 Feb;132(2):365-74. PMID: 21993558.
Roberti MP, Barrio MM, Bravo AI, Rocca YS, Arriaga JM, Bianchini M, Mordoh J, Levy EM. “IL-15 and IL-2 increase Cetuximab-mediated cellular cytotoxicity against triple negative breast cancer cell lines expressing EGFR.” Breast Cancer Res Treat.2011 Nov; 130(2):465-75. PMID: 21308409.
Levy EM, Sycz G, Arriaga JM, Barrio MM, von Euw EM, Morales SB, González M, Mordoh J, Bianchini M. “Cetuximab-mediated cellular cytotoxicity is inhibited by HLA-E membrane expression in colon cancer cells.” Innate Immun. 2009 Apr;15(2):91-100. PMID: 19318419.
